Big news for NetraMark! The Company aims to revolutionize the clinical trial process for pharmaceutical and biotech companies - improving time efficiency, reducing costs, and increasing success rates. The software company has developed its own artificial intelligence for this purpose. Yesterday, NetraMark entered into a global partnership with a leading contract research organization (CRO). The partner is active in more than 60 countries with over 3,500 employees, and plans to use NetraMark's AI in its studies in the future. This could be the breakthrough for the AI specialist, potentially ending the stock's consolidation phase. With a market capitalization of less than CAD 100 million, the stock could have significant upside potential.
time to read: 3 minutes
|
Author:
Fabian Lorenz
ISIN:
NETRAMARK HOLDINGS INC | CA64119M1059
Table of contents:
Author
Fabian Lorenz
For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.
Tag cloud
Shares cloud
NetraMark Holdings: AI-biotech play with an interesting entry opportunity
Clinical trials are known to be expensive and time-consuming. And then there are also the uncertain prospects of success. It is precisely these challenges that NetraMark aims to solve by using AI-powered precision analytics, thereby reducing the pharmaceutical and biotech industry costs, accelerating the development of new drugs, and significantly increasing the probability of success.
Pharma and biotech companies can reduce costs through AI
To this end, the Company has developed NetraAI, a proprietary software that addresses one of the biggest challenges of using AI in drug research: relatively small data sets. Typically, AI requires massive amounts of data to generate meaningful insights, which is why many AI companies avoid clinical trials altogether. NetraAI solves the problem by using explainable subsets to derive insights and hypotheses, including factors influencing treatment and placebo responses, as well as adverse events, that can potentially increase the chances of clinical trial success.
Partnership with Worldwide Clinical Trials could be the breakthrough
Yesterday, a strategic partnership with Worldwide Clinical Trials (Worldwide) was announced. Worldwide is a global contract research organization (CRO). With more than 3,500 employees in over 60 countries, Worldwide conducts clinical trials for pharmaceutical and biotech companies. In the future, Worldwide will offer its customers the NetraAI platform to optimize their studies.
The two partners are convinced that the combination of over 30 years of clinical research experience and the new AI technology will revolutionize the way studies are designed and conducted. It is expected that the number of patients required per study will decrease, study durations will be shorter, costs will decrease, and ultimately, success rates will increase, leading to the development of more new drugs to treat diseases.
Newly defined standard for precision and speed in clinical trials
Initially, NetraMark's AI will be used primarily in Worldwide's Phase 2 clinical trials in the fields of neuroscience and oncology, as well as in selected Phase 3 clinical trials. However, the AI will then also be available to all Worldwide clients in all therapeutic areas and phases of clinical development.
"By integrating NetraAI into Worldwide's global clinical infrastructure, we are enabling sponsors to better understand patient response dynamics, reduce placebo variability, and increase the likelihood of regulatory success," said George Achilleos, CEO of NetraMark. "Worldwide's new service offering will deliver a redefined standard for precision and speed in clinical trials."
NetraAI has already proven itself in clinical trials
In early March, NetraMark presented two significant studies on major depressive disorder (MDD) and schizophrenia at the International Society for CNS Clinical Trials and Methodology (ISCTM) conference. Both studies confirmed the capabilities of the NetraAI platform in clinical trial settings. In the MDD study, for example, NetraAI-driven analysis of patient subpopulations achieved a 28% increase in model accuracy compared to conventional ML approaches. Sensitivity was improved by 31%, and specificity increased by 51%.
Conclusion: Huge potential, low valuation
Clinical trials cost pharmaceutical and biotech companies more than USD 60 billion annually – and the trend is rising. This illustrates the immense opportunities for NetraMark. With the current partnership, a breakthrough could come as early as this year. With a market capitalization of less than CAD 100 million, the stock appears too cheap for an AI company operating in an exciting and specialized niche.
At the IIF investor conference a few weeks ago, NetraMark's management made a positive impression, clearly outlining why the Company is one of the leading providers of AI software for clinical trial analysis.
Lyndsay Malchuk of Stockhouse had the opportunity to ask the company leader in an interview interview about the latest company announcement:
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.
